<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04031677</url>
  </required_header>
  <id_info>
    <org_study_id>EORTC 1809-STBSG</org_study_id>
    <nct_id>NCT04031677</nct_id>
  </id_info>
  <brief_title>Surgery With Our Without Neoadjuvant Chemotherapy in High Risk RetroPeritoneal Sarcoma</brief_title>
  <acronym>STRASS2</acronym>
  <official_title>A Randomized Phase III Study of Neoadjuvant Chemotherapy Followed by Surgery Versus Surgery Alone for Patients With High Risk RetroPeritoneal Sarcoma (RPS)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>European Organisation for Research and Treatment of Cancer - EORTC</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Canadian Cancer Trials Group</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Eastern Cooperative Oncology Group</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Anticancer Fund, Belgium</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Australia and New Zealand Sarcoma Association</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>European Organisation for Research and Treatment of Cancer - EORTC</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multicenter, randomized, open label phase lll trial to assess whether preoperative&#xD;
      chemotherapy, as an adjunct to curative-intent surgery, improves the prognosis of high risk&#xD;
      DDLPS (dedifferentiated Liposarcoma) and LMS (Leiomyosarcoma) patients as measured by disease&#xD;
      free survival.&#xD;
&#xD;
      After confirmation of eligibility criteria, patients will be randomized to either the&#xD;
      standard arm or experimental arm.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Standard arm:&#xD;
&#xD;
        -  Large en-bloc curative-intent surgery within 4 weeks following randomization-&#xD;
           Experimental arm&#xD;
&#xD;
      Experimental arm:&#xD;
&#xD;
        -  3 cycles of neoadjuvant chemotherapy starting within 2 weeks following randomization:&#xD;
&#xD;
             -  High grade LPS: ADM (doxorubicin) 75 mg/m2 (or the equivalent EpiADM 120 mg/m2) +&#xD;
                ifosfamide 9 g/m3 Q3 weeks.&#xD;
&#xD;
             -  LMS: ADM 75 mg/m2 + DTIC (dacarbazine) 1 g/m2 Q3 weeks&#xD;
&#xD;
        -  re-assessment of operability&#xD;
&#xD;
        -  curative-intent surgery within 3-6 weeks of last cycle of chemotherapy&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 6, 2020</start_date>
  <completion_date type="Anticipated">April 21, 2028</completion_date>
  <primary_completion_date type="Anticipated">April 21, 2027</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Disease free survival</measure>
    <time_frame>7 years from first patient in</time_frame>
    <description>Disease free survival will be measured from the data of randomization (as reference) to the date of recurrence or death, whichever occurs first.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>8 years from first patient in</time_frame>
    <description>OS will be measured from the date of randomization to the date of death, whatever the cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Local recurrence free survival</measure>
    <time_frame>8 years from first patient in</time_frame>
    <description>Local recurrence free survival will be measured from the date of randomization to the date of recurrence (local) or death, whichever occurs first.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Recurrence free survival</measure>
    <time_frame>8 years from first patient in</time_frame>
    <description>Recurrence free survival will be measured from the date of randomization to the date of recurrence (local or distant) or death, whichever occurs first.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Distant metastases free survival</measure>
    <time_frame>8 years from first patient in</time_frame>
    <description>Distant metastases free survival will be measured from the date of randomization to the date of distant metastases or death, whichever occurs first.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">250</enrollment>
  <condition>Retroperitoneal Sarcoma</condition>
  <condition>Liposarcoma</condition>
  <condition>Leiomyosarcoma</condition>
  <arm_group>
    <arm_group_label>Standard arm</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Surgery alone</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Experimental arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Preoperative chemotherapy and surgery</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Surgery</intervention_name>
    <description>Large en-bloc curative-intent surgery</description>
    <arm_group_label>Standard arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Preoperative chemotherapy</intervention_name>
    <description>- High grade LPS: ADM 75 mg/m2 (or the equivalent EpiADM 120 mg/m2) + ifosfamide 9 g/m2 Q3 weeks&#xD;
Note: the recommended dose of Ifosfamide can be modified according to national/institutional guidelines, given that the minimum threshold must be 7.5 g/m2 per cycle.&#xD;
- LMS: ADM 75 mg/m2 + DTIC 1g/m2 Q3 weeks</description>
    <arm_group_label>Experimental arm</arm_group_label>
    <other_name>neoadjuvant chemotherapy</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically proven primary high risk leiomyosarcoma (LMS) or Liposarcoma (LPS) of&#xD;
             retroperitoneal space or infra-peritoneal spaces of pelvis.&#xD;
&#xD;
          -  LMS:&#xD;
&#xD;
               -  Grades 2 and 3 of LMS can be included&#xD;
&#xD;
               -  Minimum size of LMS tumor should be 5 cm&#xD;
&#xD;
          -  LPS:&#xD;
&#xD;
               -  Diagnosis should be confirmed based on MDM2 (Mouse double minute 2 homolog) and&#xD;
                  CDK4 (Cyclin-dependent kinase 4) expression on IHC (immunohistochemistry), while&#xD;
                  proof of MDM2 amplification is highly recommended.&#xD;
&#xD;
               -  All grade 3 DDLPS can be included.&#xD;
&#xD;
               -  DDLPS with confirmed grade 2 on biopsy can be included when:&#xD;
&#xD;
                    -  The grade 2 DDLPS has an FNCLCC score=5 (Fédération Nationale des Centres de&#xD;
                       Lutte Contre Le Cancer), has no necrosis on the biopsy but clear necrosis on&#xD;
                       imaging.&#xD;
&#xD;
                    -  The tumors carry a high risk gene profile as determined by the Complexity&#xD;
                       INdex in SARComas (CINSARC-high)&#xD;
&#xD;
          -  Representative formalin fixed, paraffin embedded tumor blocks or unstained tissue&#xD;
             slides must be available at baseline for histological central review.&#xD;
&#xD;
          -  Unifocal tumor&#xD;
&#xD;
          -  Absence of extension through the sciatic notch or across the diaphragm&#xD;
&#xD;
          -  Resectable tumor: resectability is based on pre-operative imaging (CT-abdomen,&#xD;
             potentially also with MRI) and has to be defined by the local treating sarcoma team. A&#xD;
             patients is not considered resectable when the expectation is that only an R2&#xD;
             resection is feasible.&#xD;
&#xD;
               -  Criteria for non-resectability are:&#xD;
&#xD;
                    -  Involvement of the superior mesenteric artery, aorta, coeliac trunk and/or&#xD;
                       portal vein&#xD;
&#xD;
                    -  Involvement of bone&#xD;
&#xD;
                    -  Growth into the spinal canal&#xD;
&#xD;
                    -  Progression of retro-hepatic inferior vena cava leiomyosarcoma towards the&#xD;
                       right atrium&#xD;
&#xD;
                    -  Infiltration of multiple major organs like liver, pancreas and/or major&#xD;
                       vessels&#xD;
&#xD;
          -  Tumor not previously treated (no previous surgery (excluding diagnostic biopsy),&#xD;
             radiotherapy or systemic therapy)&#xD;
&#xD;
          -  Patient must have radiologically measurable disease (RECIST 1.1), as confirmed by&#xD;
             imaging within the 28 days prior to randomization. CT thorax abdomen pelvis with IV&#xD;
             contrast is the preferred imaging modality. In case of any contra-indications (medical&#xD;
             or regulatory), it is allowed to perform a non-contrast CT thorax + MRI abdomen &amp;&#xD;
             pelvis.&#xD;
&#xD;
          -  ≥ 18 years old (no upper age limit)&#xD;
&#xD;
          -  WHO (World Health Organization) performance status ≤ 2&#xD;
&#xD;
          -  Adequate haematological and organ function:&#xD;
&#xD;
               -  Haematological: haemoglobin &gt; 9.0 g/dL or 5.6 mmol/L, absolute neutrophils &gt; 1.5&#xD;
                  x 109/L, platelets &gt; 100 x 109/L Note: Platelet transfusions is allowed to&#xD;
                  achieve these baseline values&#xD;
&#xD;
               -  Renal: estimated glomerular filtration rate (eGFR) &gt; 50 ml/min/m2; No proteinuria&#xD;
                  CTCAE ≥ grade 2;&#xD;
&#xD;
               -  Hepatic: Bilirubin ≤ 1.0 times upper limit of normal (1.0xULN) of institutional&#xD;
                  limits, ALT (alanine aminotransferase) and/or AST (aspartate transaminase) ≤1.5 x&#xD;
                  ULN. If isolated elevated bilirubin &lt;2 x ULN and Gilberts syndrome suspected,&#xD;
                  suggest repeating bloods after food. If bilirubin improves to meet the criteria&#xD;
                  above this is acceptable. More severe persistent hepatic impairment of whatever&#xD;
                  cause would exclude the patient from treatment till resolved.&#xD;
&#xD;
               -  Heart: Clinically normal cardiac function based on left ventricular ejection&#xD;
                  fraction (LVEF ≥ 50%) as assessed either by multi-gated acquisition scan (MUGA)&#xD;
                  or cardiac ultrasound and 12 lead ECG without clinically relevant abnormalities.&#xD;
&#xD;
          -  American Society of Anesthesiologist (ASA) score &lt; 3&#xD;
&#xD;
          -  Women of child bearing potential (WOCBP) must have a negative serum pregnancy test&#xD;
             within 7 days prior to the first dose of study treatment or surgery.&#xD;
&#xD;
        Note: a woman is considered of childbearing potential (WOCBP), i.e. fertile, following&#xD;
        menarche and until becoming post menopausal unless permanently sterile.&#xD;
&#xD;
        Permanent sterilisation methods include hysterectomy, bilateral salpingectomy and bilateral&#xD;
        oophorectomy.&#xD;
&#xD;
        A postmenopausal state is defined as no menses for 12 months without an alternative medical&#xD;
        cause. A high follicle stimulating hormone (FSH) level in the postmenopausal range may be&#xD;
        used to confirm a post-menopausal state in women not using hormonal contraception or&#xD;
        hormonal replacement therapy. However in the absence of 12 months of amenorrhea, a single&#xD;
        FSH measurement is insufficient..&#xD;
&#xD;
          -  Patients of childbearing / reproductive potential should use highly effective birth&#xD;
             control measures, as defined by the investigator, during the study treatment period&#xD;
             and for at least 6 months after the last dose of treatment or date of surgery. A&#xD;
             highly effective method of birth control is defined as a method which results in a low&#xD;
             failure rate (i.e. less than 1% per year) when used consistently and correctly. Such&#xD;
             methods include:&#xD;
&#xD;
               -  Combined (oestrogen and progestogen containing) hormonal contraception associated&#xD;
                  with inhibition of ovulation (oral, intravaginal, transdermal)&#xD;
&#xD;
               -  Progestogen-only hormonal contraception associated with inhibition of ovulation&#xD;
                  (oral, injectable, implantable)&#xD;
&#xD;
               -  Intrauterine device (IUD)&#xD;
&#xD;
               -  Intrauterine hormone-releasing system (IUS)&#xD;
&#xD;
               -  Bilateral tubal occlusion&#xD;
&#xD;
               -  Vasectomized partner&#xD;
&#xD;
               -  Sexual abstinence (the reliability of sexual abstinence needs to be evaluated in&#xD;
                  relation to the duration of the clinical trial and the preferred and usual&#xD;
                  lifestyle of the patient)&#xD;
&#xD;
          -  Female subjects who are breast feeding should discontinue nursing prior to the first&#xD;
             day of study treatment and until 6 months after the last study treatment.&#xD;
&#xD;
          -  Before patient registration/randomization, written informed consent must be given&#xD;
             according to ICH/GCP, and national/local regulations.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Sarcoma originated from bone structure, abdominal or gynecological viscera&#xD;
&#xD;
          -  Metastatic disease&#xD;
&#xD;
          -  Tumors with extension through the sciatic notch or across the diaphragm&#xD;
&#xD;
          -  Hypersensitivity to doxorubicin, ifosfamide, dacarbazine or to any of their&#xD;
             metabolites or to any of their excipients&#xD;
&#xD;
          -  Persistent myelosuppression&#xD;
&#xD;
          -  Myocardial infarction within the last 6 months&#xD;
&#xD;
          -  Uncontrolled cardiac arrhythmia&#xD;
&#xD;
          -  Previous treatment with maximum cumulative doses (450mg/m² Doxorubicin or equivalent&#xD;
             900mg/m² EpiADM) of doxorubicin, daunorubicin, epirubicin, idarubicin, and/or other&#xD;
             anthracyclines and anthracenediones&#xD;
&#xD;
          -  Active and uncontrolled infections&#xD;
&#xD;
          -  Vaccination with live vaccines within 30 days prior to study entry&#xD;
&#xD;
          -  Inflammation of the urinary bladder (interstitial cystitis) and/or obstructions of the&#xD;
             urine flow.&#xD;
&#xD;
          -  Other invasive malignancy within 5 years, with the exception of adequately treated&#xD;
             non-melanoma skin cancer, localized cervical cancer, localized and presumably cured&#xD;
             prostate cancer.&#xD;
&#xD;
          -  Uncontrolled severe illness, infection,medical condition (including, uncontrolled&#xD;
             diabetes or hypertension), other than the Primary LPS or LMS of the retroperitoneum.&#xD;
&#xD;
          -  Female patients who are pregnant or breastfeeding or female and male patients of&#xD;
             reproductive potential who are not willing to employ effective birth control method.&#xD;
&#xD;
          -  Any psychological, familial, sociological or geographical condition potentially&#xD;
             hampering compliance with the study protocol and follow-up schedule; those conditions&#xD;
             should be discussed with the patient before randomization in the trial&#xD;
&#xD;
          -  Known contraindication to imaging tracer and to MRI&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alessandro Gronchi</last_name>
    <role>Study Chair</role>
    <affiliation>Fondazione IRCCS Istituto Nazionale dei Tumori, Milano</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Winan van Houdt</last_name>
    <role>Study Chair</role>
    <affiliation>The Netherlands Cancer Institute-Antoni Van Leeuwenhoekziekenhuis</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>EORTC HQ</last_name>
    <phone>+3227741611</phone>
    <email>1809@eortc.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Masaryk Memorial Cancer Institute</name>
      <address>
        <city>Brno</city>
        <zip>656 53</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dagmar Adamkova Krakorova</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Leon Berard</name>
      <address>
        <city>Lyon</city>
        <zip>69008</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mehdi Brahmi</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut du Cancer de Montpellier</name>
      <address>
        <city>Montpellier</city>
        <zip>34298</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sebastien Carrere</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut Curie- Hopital de Paris</name>
      <address>
        <city>Paris</city>
        <zip>75248</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sylvie Bonvalot</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hopitaux Universitaires de Strasbourg - Hautepierre</name>
      <address>
        <city>Strasbourg</city>
        <zip>67098</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean-Baptiste Delhorme</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut Gustave Roussy</name>
      <address>
        <city>Villejuif</city>
        <zip>94805</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Matthieu Faron</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Carl Gustav Carus</name>
      <address>
        <city>Dresden</city>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephan Richter</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>UniversitaetsMedizin Mannheim</name>
      <address>
        <city>Mannheim</city>
        <zip>68167</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bernd Kasper</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centro Di Riferimento Oncologico</name>
      <address>
        <city>Aviano</city>
        <zip>33081</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Angela Buonadonna</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>IRCCS - Fondazione Piemonte Inst di Candiolo</name>
      <address>
        <city>Candiolo</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Giovanni Grignani</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) &quot;Dino Amadori&quot;</name>
      <address>
        <city>Meldola</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lorena Gurrieri</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Istituto Clinico Humanitas</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vittorio Quagliuolo</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Istituto Europeo di Oncologia</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pennacchioli Elisabetta</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>IRCCS - Istituto Nazionale dei Tumori</name>
      <address>
        <city>Milan</city>
        <zip>20133</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alessandro Gronchi</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>IRCCS - Istituto Oncologico Veneto</name>
      <address>
        <city>Padova</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marco Rastrelli</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Policlinico Universitario Campus Bio-Medico- Oncology Center</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vincenzi Bruno</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Maria Sklodowska-Curie Memorial Cancer Centre - Maria Sklodowska-Curie National Research Institute of Oncology</name>
      <address>
        <city>Warsaw</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Piotr Rutkowski</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>National Cancer Institute</name>
      <address>
        <city>Bratislava</city>
        <zip>SK 833 10</zip>
        <country>Slovakia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jozef Sufliarsky</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital De La Santa Creu I Sant Pau</name>
      <address>
        <city>Barcelona</city>
        <zip>08041</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ana Garcia Sebio</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut Catala d'Oncologia - ICO Badalona - Hospital Germans Trias i Pujol</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marc Cucurull-Salermo</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario San Carlos</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Casado</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>NHS Greater Glasgow and Clyde - Beatson West of Scotland Cancer Centre - Gartnavel General Hospital</name>
      <address>
        <city>Glasgow</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ioanna Nixon</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>the Royal Marsden Hospital</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dirk Strauss</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Czechia</country>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Poland</country>
    <country>Slovakia</country>
    <country>Spain</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>July 22, 2019</study_first_submitted>
  <study_first_submitted_qc>July 22, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 24, 2019</study_first_posted>
  <last_update_submitted>July 14, 2021</last_update_submitted>
  <last_update_submitted_qc>July 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sarcoma</mesh_term>
    <mesh_term>Leiomyosarcoma</mesh_term>
    <mesh_term>Liposarcoma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

